[Development of a new antidepressant : agomelatine].
There are now many potentials for the development of more effective, better tolerated, and more rapidly acting antidepressants acting in association and/or beyond the monoamine hypothesis. One of these possibilities is the development of antidepressant drugs with melatonin agonist property. This holds much promise since various affective disorders, including depression, are characterized by abnormal patterns of circadian rhythms. In line with this, the melatoninergic agonist properties of agomelatine, an antidepressant with proven clinical efficacy, may represent a new concept for the treatment of depression. By way of behavioral studies in rodents, it has been shown that administration of agomelatine can mimic the action of melatonin in the synchronization of circadian rhythm patterns. Interest in agomelatine has increased in recent times due to its prospective use as a novel antidepressant agent, as demonstrated in a number of animal studies using well-validated animal models of depression (including the forced swimming test, the learned helplessness, the chronic mild stress). Interestingly, the melatoninergic agonist property of agomelatine may not, alone, be sufficient to sustain its clear antidepressant-like activity. Recent results from receptor binding and in vivo studies gave support to the notion that agomelatine's effects are also mediated via its function as a competitive antagonist at the 5-HT2C receptor. Finally, thanks to its absence of binding with a broad range of receptors and enzymes, agomelatine is particularly safe and devoid of all the deleterious effects reported with tricyclics and SSRIs.
Mocaër
Elisabeth
E
Groupe de recherche Servier, Servier International, Neuilly-sur-Seine, France. elisabeth.mocaer@fr.netgrs.com
Delalleau
Bruno
B
Boyer
Pierre-Alain
PA
de Bodinat
Christian
C
D000081:Acetamides / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D002940:Circadian Rhythm; D003866:Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D004195:Disease Models, Animal; D006801:Humans; D006993:Hypnotics and Sedatives / Q000494:pharmacology* / Q000627:therapeutic use*; D008550:Melatonin / Q000502:physiology; D044405:Receptor, Serotonin, 5-HT2C / Q000502:physiology; D009281:Naphthalenes
D000081:Acetamides; D006993:Hypnotics and Sedatives; D008550:Melatonin; D044405:Receptor, Serotonin, 5-HT2C; C084711:agomelatine; D009281:Naphthalenes